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Abstract
Suppression of type II collagen (COL2A1) cleavage by
transforming growth factor (TGF)-β2 in cultured human
osteoarthritic cartilage has been shown to be associated with
decreased expression of collagenases, cytokines, genes
associated with chondrocyte hypertrophy, and upregulation of
prostaglandin (PG)E2 production. This results in a normalization
of chondrocyte phenotypic expression. Here we tested the
hypothesis that PGE2 is associated with the suppressive effects
of TGF-β2 in osteoarthritic (OA) cartilage and is itself capable of
downregulating collagen cleavage and hypertrophy in human
OA articular cartilage. Full-depth explants of human OA knee
articular cartilage from arthroplasty were cultured with a wide
range of concentrations of exogenous PGE2 (1 pg/ml to 10 ng/
ml). COL2A1 cleavage was measured by ELISA. Proteoglycan
content was determined by a colorimetric assay. Gene
expression studies were performed with real-time PCR. In
explants from patients with OA, collagenase-mediated COL2A1
cleavage was frequently downregulated at 10 pg/ml (in the
range 1 pg/ml to 10 ng/ml) by PGE2 as well as by 5 ng/ml TGF-
β2. In control OA cultures (no additions) there was an inverse
relationship between PGE2 concentration (range 0 to 70 pg/ml)
and collagen cleavage. None of these concentrations of added
PGE2 inhibited the degradation of proteoglycan (aggrecan).
Real-time PCR analysis of articular cartilage from five patients
with OA revealed that PGE2  at 10 pg/ml suppressed the
expression of matrix metalloproteinase (MMP)-13 and to a
smaller extent MMP-1, as well as the proinflammatory cytokines
IL-1β and TNF-α and type X collagen (COL10A1), the last of
these being a marker of chondrocyte hypertrophy. These studies
show that PGE2  at concentrations much lower than those
generated in inflammation is often chondroprotective in that it is
frequently capable of selectively suppressing the excessive
collagenase-mediated COL2A1 cleavage found in OA cartilage.
The results also show that chondrocyte hypertrophy in OA
articular cartilage is functionally linked to this increased
cleavage and is often suppressed by these low concentrations
of added PGE2. Together these initial observations reveal the
importance of very low concentrations of PGE2 in maintaining a
more normal chondrocyte phenotype.
COL10A1 = type X collagen; COL2A1 = type II collagen; COX = cyclooxygenase; DMEM = Dulbecco's modified Eagle's medium; ELISA = enzyme-
linked immunosorbent assay; GAG = glycosaminoglycan; GAPDH = glyceraldehyde-3-phosphate dehydrogenase; IL = interleukin; MMP = matrix 
metalloproteinase; OA = osteoarthritis; PCR = polymerase chain reaction; PG = prostaglandin; PGE2 = prostaglandin E2; PGES-1 = prostaglandin 
E synthase-1; TGF-β2 = transforming growth factor-β2; TNF-α = tumor necrosis factor-α.Arthritis Research & Therapy    Vol 9 No 4    Tchetina et al.
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Introduction
Osteoarthritis (OA) is a systemic condition that can affect sin-
gle or multiple joints and involves degenerative changes in the
articular cartilage, remodeling of subchondral bone and limited
synovial inflammation [1]. Osteoarthritic changes in articular
cartilage involve progressive proteolytic degradation of its
extracellular matrix, composed mainly of type II collagen
(COL2A1) and aggrecan, eventually leading to a loss of the
cartilage. This involves phenotypic hypertrophy-related
changes in chondrocytes, such as the production of type X
collagen (COL10A1) (hypertrophy marker), and the upregula-
tion of collagenase matrix metalloproteinase (MMP)-13, as is
seen in the fetal growth plate [1-3].
Joint inflammation in OA causes an increased synthesis of
cyclooxygenase (COX)-2-dependent prostaglandins (PGs),
which sensitize peripheral nociceptor terminals and produce
localized sensitivity to pain [4]. Non-steroidal anti-inflammatory
drugs and specific COX-2 inhibitors are therefore most widely
used as painkillers to inhibit prostaglandin production by COX.
Prostaglandins, especially PGE2, the major PG synthesized by
cartilage [5], are spontaneously released by OA cartilages in
amounts 50-fold higher than in normal cartilage and 18-fold
higher than in normal cartilage stimulated by cytokines [6].
Strong upregulation of COX-2 expression in arthritic synovial
membranes and cartilage has led to the suggestion that the
selective inhibition of COX-2 may result in an amelioration of
arthritic conditions [7].
However, PGE2, generated by chondrocytes, has been shown
to be physiologically important for maintaining cartilage home-
ostasis [6]. Because COX-2 is expressed physiologically in
some tissues such as glomeruli and cortex, it may have an anti-
inflammatory effect [4,8]. It can be protective in OA articular
cartilage because it inhibits the expression of IL-1β-induced
collagenase and stromelysin in human and animal synovial
fibroblasts [9,10], and stimulates collagen and proteoglycan
synthesis [11-13] and chondrocyte proliferation [11,14].
Moreover we showed recently that the growth factor TGF-β2
is capable of suppressing chondrocyte hypertrophy and differ-
entiation, collagenase expression, collagen cleavage and the
expression of proinflammatory cytokines in cultured OA artic-
ular cartilages [3]. This is accompanied by the upregulation of
prostaglandin E synthase-1 (PGES-1) expression and PGE2
release. Here we test the hypothesis that PGE2 alone can
inhibit collagen degradation in OA articular cartilage, and pro-
vide evidence in support of it.
Materials and methods
Patients
Human femoral condylar cartilages were obtained at total knee
arthroplasty from 19 patients (n = 4 men, mean age 73.7 ± 6.4
years, range 66 to 80 years; n = 15 women, mean age 77.2 ±
11.3 years, range 50 to 90 years) with OA diagnosed in
accordance with the criteria of the American College of Rheu-
matology [15]. The study was approved by McGill University
Ethics Review Board.
Isolation and preparation of cartilage
Femoral condylar articular cartilages were isolated and pre-
pared for culture as described previously [3,16]. All cartilages
exhibited macroscopic articular surface differences from nor-
mal cartilages. To generate sufficient cartilage to perform each
of these analyses on a patient, all of the available articular car-
tilage from each patient, regardless of the degree of degener-
ation (Mankin grades 4 to 12), was used, as described
previously [3,17,18]. In brief, OA articular cartilages were
washed three times with DMEM (Gibco BRL, Life Technolo-
gies, Grand Island, NY, USA) containing 20 mM HEPES (4-(2-
hydroxyethyl)-1-piperazine ethanesulfonic acid) buffer pH 7.4
(Gibco BRL), 45 mM NaHCO3, 100 units/ml penicillin, 100
μg/ml streptomycin and 150 μg/ml gentamycin sulphate. Full-
depth cartilage slices from a single site, about 20 mm × 20
mm, were cut vertical to the articular surface and then into
cubes of about 2 mm × 2 mm. Five to seven cubes were ran-
domly obtained and wet weights of about 60 mg were distrib-
uted in each culture well (48-well Costar 3548 plate; Corning
Inc., Corning, NY, USA). Samples were maintained before cul-
ture for 48 hours at 37°C in 1 ml per well of medium A in 95%
air/5% CO2.
In these and our previous studies of these human knee OA
cartilages we used a standard sampling procedure [8,19]. OA
femoral condylar cartilages show variations in cartilage thick-
ness and various degrees of degradation between weight-
bearing and non-weight-bearing regions. These result in varia-
tion between samples, although we do our best to finely chop,
mix and randomly distribute the tissue in our culture wells from
a given joint and person. In spite of this variability we observed
a significant difference in collagen cleavage activity between
PGE2-treated cartilage explants and the untreated controls.
The amount of OA cartilage, which is always macroscopically
different from normal, is always limiting. We did not use
Mankin grading because the degeneration is very variable
within the joint and, as in the previous studies, we had to use
all the cartilage available from each patient to be able to per-
form these analyses, otherwise it would not have been possi-
ble to conduct the experiments. This mixture of finely chopped
cartilages therefore represents different degrees of degenera-
tion existing within a given joint, from Mankin grade 4 to grade
12.
Cartilage explant culture
Media were changed after 48 hours (day 0) and thereafter
were replaced every 4 days. Final concentrations of 1 pg/ml to
10 ng/ml PGE2 (Sigma Chemical Co., St. Louis, Mo, USA) or
5 ng/ml TGF-β2 (R&D Systems, Minneapolis, MN, USA) were
freshly added to medium A from day 0 at each mediumAvailable online http://arthritis-research.com/content/9/4/R75
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change. The cartilage (triplicate cultures for each analytical
point) was cultured for a total of 16 days and analyzed at day
16 for COL2A1 cleavage by collagenases and proteoglycan
release. The conditioned media were collected every 4 days at
each medium change from day 4 to day 16 and stored at -
20°C until analyzed. For analyses of gene expression, separate
cultures were maintained for up to 48 hours and analyzed as
described below.
ELISA assays of collagenase-cleaved type II collagen
The OA cartilage explants from day 16 of culture were
digested and extracted with α-chymotrypsin to solubilize
denatured collagen including the carboxy-terminal neoepitope
COL2–3/4C short (C1,2C) epitope generated by the cleav-
age of COL2A1 by collagenase. This was measured as
described previously in α-chymotrypsin extracts and condi-
tioned media by ELISA [17,18]. Total amount of cleavage
neoepitope in cartilages and media was calculated by summa-
tion of the data from each medium change and cartilage anal-
ysis. Results were expressed as pmoles of epitope per mg wet
weight of cartilage, based on a molecular mass of the standard
peptide epitope of 608 Da.
Determination of proteoglycan content and release
This was determined in cartilage extracts and conditioned
media as sulfated glycosaminoglycans (GAGs), which is pri-
marily a measure of proteoglycan aggrecan content, using a
modification of the colorimetric 1,9-dimethylmethylene blue
dye-binding assay [20]. Cumulative proteoglycan release
(GAG in the medium) and its content in cartilages (GAG in the
cartilage) were expressed as mirograms of GAG per milligram
wet weight of cartilage. GAG release into medium was repre-
sented as a percentage of the total cumulative GAG in the car-
tilage plus cumulative GAG release into medium. This
provides an accurate measure of release, accounting for the
marked variation in cartilage GAG content in OA cartilage
[18,21].
Quantification of PGE2 release
PGE2 concentrations were determined in the control undiluted
conditioned media collected at each medium change, which
were then pooled for analysis with a commercially available
competitive ELISA kit (Cayman Chemical Company, Ann
Arbor, MI, USA,) in accordance with the manufacturer's
instructions. Results were expressed in picograms per milli-
gram wet weight of cartilage. PGE2 standards provided with
the kit were diluted with DMEM.
Total RNA isolation
Total RNA isolation for the detection of gene expression was
based on methodology previously described [3]. This was iso-
lated from articular cartilage explants or isolated chondrocytes
after up to 96 hours in culture as indicated in the Results sec-
tion. Fresh cartilage tissue or cells in solution D (4 M guanidine
isothiocyanate, 25 mM sodium citrate pH 7.0, 0.5% laurylsar-
cosine, 0.1 M 2-mercaptoethanol) were immediately frozen in
liquid nitrogen and kept at -80°C until all samples had been
collected. Samples were defrosted at 21–23°C and then vor-
tex-mixed vigorously for 30 minutes. The debris was removed
by centrifugation at 5,000 g for 10 minutes at 4°C. Proteins
and nucleic acids in the supernatant were precipitated with 1
volume of propan-2-ol overnight at -20°C. The precipitate was
removed at 10,000 g for 20 minutes at 4°C and resuspended
in digestion buffer (10 mM Tris-HCl pH 8.0, 5 mM ethylenedi-
aminetetraacetic acid, 1% SDS, with 2 mg/ml Proteinase K
(Gibco BRL)) and incubated at 50°C until the pellet disap-
peared. After extraction with a mixture containing 1 volume of
phenol, 0.2 volumes of chloroform and 0.1 volume of 2 M
sodium acetate pH 4.0, the aqueous phase was recovered by
centrifugation (10,000 g for 30 minutes at 4°C). An equal vol-
ume of 70% ethanol was added to each sample aqueous
phase and loaded on an RNeasy spin column (Qiagen, Valen-
cia, CA, USA). Further RNA purification was performed with
an RNeasy kit (Qiagen) in accordance with the manufacturer's
instructions.
Reverse transcriptase reaction
The reverse transcriptase reaction was performed with total
RNA isolated from articular cartilage explants and SuperScript
TMII H- Reverse Transcriptase as recommended by Gibco
BRL-Invitrogen, (Burlington, ON, Canada) and as described
previously [3].
Real-time quantitative PCR
Preformed primers and probes for the TaqMan assay (Applied
Biosystems, Foster City, CA, USA) of human genes used in
this study were MMP-13 Applied Biosystems, TaqMan Gene
Expression Assays, accession no. Hs00233992_m1),
COL10A1 (Hs00166657_m1), MMP-1(Hs00233958_m1),
IL-1β (Hs00174097_m1) and TNF-α (Hs00174128_m1).
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH), β-
actin, 18s RNA and cyclophilin were examined as endogenous
controls. GAPDH has been chosen for the final data presenta-
tion because it gives the lowest variation.
Quantification of gene expression levels of mRNA was per-
formed with a 7500 Real-time PCR System (Applied Biosys-
tems). After treatment with 1 μl of RNase H, 1 μl of reverse
transcription product was subjected to real-time PCR in a 25
μl total reaction mixture containing 12.5 μl of TaqMan Univer-
sal PCR Master Mix (Applied Biosystems), 900 nM sense and
antisense primers, 50 nM probe, and template cDNA. After a
single step of 50°C for 2 minutes and initial activation at 95°C
for 10 minutes, reaction mixtures were subjected to 40 ampli-
fication cycles (15 seconds at 95°C for denaturation, and 1
minute of annealing and extension at 60°C).
By using a sequence detection system the threshold cycle (Ct)
was determined at which the exponential amplification of PCR
products began. After PCR, dissociation curves were gener-Arthritis Research & Therapy    Vol 9 No 4    Tchetina et al.
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ated with one peak, indicating the specificity of the amplifica-
tion. A threshold cycle (Ct value) was obtained from each
amplification curve by using SDS V 1.3 software provided by
the manufacturer.
Relative mRNA expression was determined with the ΔΔCt
method, as detailed by manufacturer guidelines (Applied Bio-
systems). A ΔCt value was calculated by subtracting the Ct
value for the housekeeping gene GAPDH from the Ct value for
each sample. A ΔΔCt value was then calculated by subtracting
the ΔCt value of the control (unstimulated cartilage) from the
ΔCt value of each treatment. Fold changes compared with the
control were determined by raising 2 to the power -ΔΔCt; that
is, 2-ΔΔCt. Each PCR was performed in duplicate on three sep-
arate occasions for each independent experiment. Three 'no
template' controls were consistently negative for each
reaction.
To avoid variation in efficiency between experiments, all sam-
ples of the same cartilage were simultaneously subjected to
reverse transcription, and all samples of cDNA were simulta-
neously amplified by real-time PCR.
The relative quantification protocol for evaluating gene expres-
sion with real-time reverse transcription-mediated PCR is
based on the comparison of gene expression level in the
treated cartilage explants and untreated cartilage control sam-
ples, both of which are normalized to the GAPDH expression
level. The expression level of each control is set to 1. We
therefore show only one control bar for all the genes measured
in the set.
The deviations in treated samples represent variations in gene
expression in triplicates of cultured cartilage from each individ-
ual. Real-time PCR reaction was performed in duplicate for
each cartilage sample.
Statistical analysis
Quantitative data are expressed as means ± SD. Assays were
run in at least triplicate. A normality test showed that data were
distributed in accordance with a Gaussian distribution curve.
To analyze treatment effects, Mann–Whitney and paired t-test
analyses were used. P < 0.05 was considered significant.
Results
Inhibition of collagenase activity by PGE2
Our previous studies of cultured human OA articular cartilage
explants have shown that conditioned media from cultures
maintained with TGF-β2 for 16 days contained concentrations
of PGE2 in the range 4 to 125 pg/ml. We used this information
to determine whether the addition of exogenous PGE2 con-
centrations in this range would influence the cleavage of
COL2A1 by collagenases in human OA explants. OA articular
cartilage explants showed significant variability in the respon-
siveness to PGE2. Collagen cleavage was downregulated by
exogenous PGE2 at concentrations as low as 0.1 pg/ml (data
not shown) and 1 pg/ml in one of four patients (Figure 1b).
However, in most examined cartilages and as shown by the
group analyses, significant downregulation of collagen cleav-
age was observed at 10 pg/ml PGE2 in these four individual
patients (Figure 1e) and in a larger cohort of 13 other patients
(Figure 1f). A mean inhibition of 39.7% (range 33.5 to 49.8%)
by 10 pg/ml PGE2 was observed and it was as effective as
TGF-β2 (40.1%; range 26.9 to 49.4%). Interestingly, at higher
concentrations (0.1 to 10 ng/ml) this inhibition was no longer
seen. In one case, stimulation was observed at 10 ng/ml PGE2
(Figure 1b).
We observed an inverse relationship between PGE2 concen-
tration and collagen cleavage activity in OA explant cultures
that served as controls by plotting PGE2 concentration versus
collagen cleavage in the control OA articular cartilage explants
(Figure 1g). An increase in PGE2 levels in OA articular carti-
lage explants was accompanied by a linear (correlation coeffi-
cient r = -0.507; P = 0.044) decrease in collagen cleavage.
Proteoglycan release in explants cultured with PGE2
Downregulation of collagen cleavage was not accompanied
by significant changes in GAG release in explants cultured in
the presence of 10 pg/ml PGE2 (Figure 2). However, TGF-β2
significantly upregulated the release of GAG in three out of
four cartilages examined.
Alterations of gene expression in OA cartilage explants 
by PGE2
In comparison with controls, OA explants from five patients
cultured in the presence of 10 pg/ml PGE2 showed decreased
expression of the genes related to chondrocyte hypertrophy,
namely those encoding COL10A1 and MMP-13 (Figure 3).
Expression of collagenase MMP-1 was significantly downreg-
ulated in four out of five patients. Cytokines were most strongly
downregulated by prostaglandin and no expression of IL-1β
(Figure 3a,c,d) or TNF-α (Figure 3a,b,c,d) was observed in
explants cultured in its presence. However, expression of cyc-
lin B2, caspase 3, TGF-β2, COX2 and PGES-1 was not sig-
nificantly affected by 10 pg/ml PGE2 (data not shown). The
data for the whole group are shown in Figure 3f. The variability
of the residual expression level of genes such as those encod-
ing IL-1 and TNF may result from the differences in cytokine
expression associated with various disease states or activities.
Discussion
COX-dependent prostaglandins have been implicated in vari-
ous physiological processes, including male fertility, menstru-
ation, ovulation, pregnancy and implantation, and in the
pathological action of different inflammatory and neoplastic
diseases, notably arthritis and cancer [4]. The potential patho-
logical effects of PGE2 on articular cartilage have also been
reported [7,22].Available online http://arthritis-research.com/content/9/4/R75
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Here we present evidence to indicate that at very low concen-
trations (10 pg/ml) exogenous PGE2 is capable of selectively
inhibiting excessive collagen cleavage seen in cultured human
OA articular cartilage explants. This is accompanied by the
downregulation of expression of the collagenases MMP-1 and
MMP-13, the cytokines IL-1β and TNF-α, and COL10A1, the
last of these being a marker of chondrocyte hypertrophy.
Moreover, we observed an inverse relationship in control cul-
tures (no added PGE2) between PGE2 content and COL2A1
cleavage. Together these results draw attention to the capac-
ity of exogenous PGE2 to suppress collagen cleavage and
PGE2 content.
It is unclear why very low exogenous concentrations of 10 pg/
ml PGE2  can suppress collagen cleavage when cultures
already contain up to 70 pg/ml PGE2. This may be related to
the fact that PGE2 activity is unstable [23]. Thus, repeated
application of PGE2 with each medium change may have been
Figure 1
Inhibition of collagen cleavage by prostaglandin E2 (PGE2) and transforming growth factor (TGF)-β2 Inhibition of collagen cleavage by prostaglandin E2 (PGE2) and transforming growth factor (TGF)-β2. (a–d) The effect of 5 ng/ml TGF-β2 and PGE2 
at various concentrations (1 pg to 10 ng/ml) on collagen cleavage in human osteoarthritic (OA) explants from patients of indicated age and gender; 
(e) means ± SDs for all four patients; (f) inhibition of type II collagen cleavage by collagenase in human OA articular explants by 10 pg/ml PGE2; (g) 
concentration relationship between PGE2 in control cultures and collagen cleavage. The average medium levels of PGE2 in the dose-dependent 
studies were as follows: 6.3 ± 1.2 pg/ml for the 77-year-old female (a); 13.9 ± 4.1 pg/ml for the 50-year-old female (b); 7.8 ± 2.1 pg/ml for the 66-
year-old male (c); and 61.6 ± 7.6 pg/ml for the 82-year-old female (d). (f) Thirteen OA articular cartilage explants were cultured with (10 pg/ml 
PGE2) or without (control) for 16 days and collagen cleavage was evaluated by the accumulation of C1,2C neoepitope in the medium and chymot-
rypsin-derived cartilage extracts. (g) The relationship between PGE2 concentration and collagen cleavage in 16 OA explants that served as controls. 
Significant differences from the control (P < 0.05) are indicated by asterisks.Arthritis Research & Therapy    Vol 9 No 4    Tchetina et al.
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enough to decrease collagen cleavage. We do not know
whether the PGE2 that we measured in cultures by immu-
noassay is active, but our results suggest that it is not.
The inhibitory effect of very low concentrations PGE2 in OA
cartilage explants may help to explain the similar inhibitory
effects produced by TGF-β2 that are accompanied by upregu-
lation of PGE2 at the levels of gene expression and secretion
Figure 2
Prostaglandin E2 (PGE2) does not affect total proteoglycan release Prostaglandin E2 (PGE2) does not affect total proteoglycan release. (a–
d) Percentage release of total proteoglycan (glycosaminoglycan (GAG) 
release) was measured in conditioned media of human osteoarthritic 
cartilage explants cultured with 5 ng/ml transforming growth factor-β2 
or PGE2 at concentrations from 1 pg/ml to 10 ng/ml. The age and sex 
of each patient are indicated. Significant differences from controls (P < 
0.05) are indicated by asterisks.
Figure 3
PGE2 downregulates the expression of genes responsible for collagen  cleavage, chondrocyte hypertrophy and inflammation PGE2 downregulates the expression of genes responsible for collagen 
cleavage, chondrocyte hypertrophy and inflammation. Relative expres-
sion with reference to glyceraldehyde-3-phosphate dehydrogenase is 
shown compared with controls for genes in osteoarthritic cartilages 
determined by real-time PCR analyses in explant cultures at 24 hours 
cultured in the presence or absence (control) of 10 pg/ml prostaglan-
din E2 (PGE2). Control bars are shown as 1.0 as required for relative 
quantification with the real-time PCR protocol. Means ± SD for all five 
patients (a–e) are shown in (f). Asterisks indicate significant differ-
ences from the control (P < 0.05). The age and sex of each patient are 
indicated. The average levels of PGE2 in the medium in the gene 
expression studies were as follows: 62.3 ± 6.1 pg/ml for the 66-year-
old female (a); 7.2 ± 1.9 pg/ml for the 53-year-old female (b); 0 pg/ml 
for the 67-year-old female (c); 65.7 ± 7.3 pg/ml for the 90-year-old 
female (d); and 30.4 ± 7.6 pg/ml for the 82-year-old female (e).Available online http://arthritis-research.com/content/9/4/R75
Page 7 of 9
(page number not for citation purposes)
[3]. The predominant inhibitory effect of PGE2 in OA cartilage
explants supports the notion that our previously observed sup-
pression of collagen cleavage by TGF-β2 may be the result of
an autocrine/paracrine feedback loop involving the
upregulation of the phospholipase A2/COX/PGES-1 axis and
eicosanoid release [3]. The effect of added PGE2 and the
interrelationships we observed in control cultures suggests an
interesting dynamic in which PGE2 in the range 0 to 70 pg/ml
released from OA specimens is associated with the suppres-
sion of collagen cleavage.
To obtain a more precise insight into the interrelationships
between PGE2 and TGF-β2 effects in OA articular cartilage,
activation of TGF-β2 with isolated chondrocytes and measure-
ment of gene expression in the presence or absence of PG
synthase inactivation by siRNA may be the best way to differ-
entiate between PGE2-dependent and PGE2-independent
signaling in cartilage protection. In preliminary studies (E. Tch-
etina, J. DiBattista, A.R. Poole, unpublished data) we have
observed that the addition of Naproxen, a PG synthase inhibi-
tor, can abrogate the inhibitory effect of TGF-β2 and enhance
collagen cleavage in the absence of this growth factor. This
also suggests that PGE2 may have a role in mediating the
action of TGF-β2 and in protecting articular cartilage from
degeneration.
Some variability was observed in the effect of PGE2 in individ-
ual patients. This may have been due to differences in the phe-
notypic expression of chondrocytes associated with the
degree of cartilage degeneration, which varies between and
w i t h i n  p a t i e n t s .  T h i s  i s  a n  i s s u e  t h a t  w e  w e r e  u n a b l e  t o
address in the present study because a lack of tissue at arthro-
plasty forced us to pool all the cartilage from each patient. Dif-
ferences between patients in response to agents that can
regulate matrix resorption have been noted previously in cul-
ture studies of this kind [3,18]. Further investigations are
clearly required to help explain these differences. However,
the present results do support our previous suggestion that
increased generation of PGE2 is associated with the predom-
inantly inhibitory effect of TGF-β2 on the collagen degeneration
in OA articular cartilage [3] and that PGE2 can suppress col-
lagen cleavage.
PGE2 was previously found to suppress chondrocyte differen-
tiation/hypertrophy in development [24,25]. Here we show
that this inhibitory effect on hypertrophy can be extended to
the pathology of OA cartilage. Chondrocyte hypertrophy,
defined by the presence of COL10A1 expression, is a recog-
nized component of the pathology involving excessive colla-
gen cleavage. Both are frequently suppressed in our studies
by very low concentrations of added PGE2. The fact that
added PGE2 is capable of suppressing the chondrocyte differ-
entiation/hypertrophy phenotype in development [24,25], and
that in our explants 10 pg/ml PGE2 also inhibits chondrocyte
terminal differentiation (registered by COL10A1 downregula-
tion), suggests that PGE2 controls collagen cleavage by sup-
pressing the increase in collagenase activity associated with
chondrocyte hypertrophy [1-3]. The simultaneous suppression
of proinflammatory cytokines that we observed also suggests
that the upregulation of IL-1 and TNF-α is associated with
hypertrophy, at least in OA. In this respect PGE2 is again very
similar to TGF-β2 in downregulating chondrocyte hypertrophy
and restoring the healthy early proliferative chondrocyte phe-
notype [3].
That chondrocyte hypertrophy is associated with cartilage
degeneration in OA is also supported by the fact that partial
deletion of RUNX-2  gene expression, which is believed to
account for chondrocyte hypertrophy and MMP-13 upregula-
tion (the two events being closely linked), retards cartilage
degeneration in a mouse surgical model [26]. Downregulation
of excessive collagen cleavage in OA by suppression of
expression of a hypertrophic phenotype could therefore be a
promising approach in controlling the disease severity.
These suppressive effects of PGE2 were seen only at much
lower concentrations than those observed in inflammation [7].
PGE2 has been reported to be responsible for both catabolic
and anabolic changes in articular cartilage [6,7]. It can inhibit
collagen synthesis in growth plate chondrocytes [27], mediate
MMP production in articular chondrocytes and cartilage
[6,28], inhibit chondrocyte proliferation [29], promote IL-1β
expression [30] and induce chondrocyte apoptosis [31]. In
contrast, it has also been shown to inhibit collagenase and
stromelysin expression [9,10,32,33] and IL-1β and TNF-α
generation [33], to stimulate collagen and proteoglycan syn-
thesis [11-13] and chondrocyte proliferation [11], and to
inhibit chondrocyte terminal differentiation/hypertrophy
[24,25] and apoptosis in endothelial cells [34].
It is important to recognize that the opposing effects of PGE2
on chondrocytes can be dependent on the dose of the agent
[9,35]. Our experimental system containing added 10 pg/ml
PGE2 produced chondroprotection on OA articular cartilage in
that it downregulated collagen cleavage and the expression of
genes associated with collagen cleavage, proinflammatory
cytokines and hypertrophy. It did not upregulate chondrocyte
proliferation and type II collagen synthesis as evidenced by the
lack of significant changes in the expression of cyclin B2 and
COL2A1, respectively. Generation of prostaglandins was also
not altered as COX-2 and PGES-1 expression remained
essentially the same. The reasons why only such low doses of
PGE2 are chondroprotective remain to be established but may
be related to receptor usage.
It is well established that EP1 and EP2 receptors for PGE2 are
low-affinity receptors, whereas EP3 and EP4 are high-affinity
receptors. Activation of the low-affinity PGE2 receptors is likely
to be important in mediating the actions of the much higher
concentrations of PGE2 found in various pathologic inflamma-Arthritis Research & Therapy    Vol 9 No 4    Tchetina et al.
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tory processes [36]. Simultaneous stimulation of EP2 and EP4
is necessary and sufficient to elicit the effect of PGE2 on the
differentiation of rat primary chondrocytes [37]. Receptor
deletion studies have shown that homozygous deletion of the
EP1, EP2 or EP3 receptors does not affect the development of
arthritis, whereas EP4  receptor-deficient mice showed
decreased incidence and severity of disease [38]. In contrast,
others have found that suppression of EP2  expression
enhances MMP-13 collagenase induction in human OA
chondrocytes [39].
Our own preliminary data on receptor involvement suggest a
role of EP3 receptor, which expression is significantly upregu-
lated on the addition of 10 pg/ml PGE2 to OA articular carti-
lage explants (E.V. Tchetina, J. DiBattista, A.R. Poole,
unpublished data). Further extensive work to identify the
receptors involved is therefore required to help explain our
observations.
Finally, it is important to recognize the fact that in the presence
of additional physiological amounts of PGE2, not only are OA
chondrocytes often capable of reverting to a more normal phe-
notype, as reflected by studies of gene expression and matrix
collagen degradation, but osteoblastic differentiation,
detected by alkaline phosphatase activity, is also enhanced
[35,40]. The present results, although preliminary, suggest the
importance of very low concentrations of PGE2 in maintaining
a healthier skeleton and specifically a more normal chondro-
cyte phenotype in ageing articular cartilage.
Conclusion
We have shown that PGE2 at low concentrations in OA carti-
lage can downregulate collagenase-dependent COL2A1
cleavage and the associated hypertrophy. This was associ-
ated with a downregulation of collagenases MMP-13 and
MMP-1, proinflammatory cytokines IL-1β and TNF-α, and
COL10A1 expression. Proteoglycan degradation was not
affected. Therefore PGE2 at concentrations much lower than
those generated in inflammation are chondroprotective and
not destructive as is commonly believed.
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